Literature DB >> 30771527

Standards for MIC testing that apply to the majority of bacterial pathogens should also be enforced for Mycobacterium tuberculosis complex.

T Schön1, E Matuschek2, S Mohamed3, M Utukuri4, S Heysell3, J-W Alffenaar5, S Shin6, E Martinez7, V Sintchenko7, F P Maurer8, P M Keller9, G Kahlmeter2, C U Köser10.   

Abstract

Entities:  

Keywords:  MIC testing; Microtiter plates; Mycobacterium tuberculosis complex; Quality control ranges; Quality control targets

Mesh：

Substances：

Year:  2019        PMID： 30771527      PMCID： PMC7903878          DOI： 10.1016/j.cmi.2019.01.019

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


× No keyword cloud information.
  3 in total

Review 1.  The 2014 Garrod Lecture: EUCAST - are we heading towards international agreement?

Authors:  Gunnar Kahlmeter
Journal:  J Antimicrob Chemother       Date:  2015-06-18       Impact factor: 5.790

2.  A Multilaboratory, Multicountry Study To Determine MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing of Selected First-Line Antituberculosis Drugs, Second-Line Injectables, Fluoroquinolones, Clofazimine, and Linezolid.

Authors:  Koné Kaniga; Daniela M Cirillo; Sven Hoffner; Nazir A Ismail; Devinder Kaur; Nacer Lounis; Beverly Metchock; Gaby E Pfyffer; Amour Venter
Journal:  J Clin Microbiol       Date:  2016-09-21       Impact factor: 5.948

3.  Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis.

Authors:  Paola M V Rancoita; Federica Cugnata; Ana Luíza Gibertoni Cruz; Philip W Fowler; Daniela M Cirillo; Emanuele Borroni; Sarah J Hoosdally; Timothy M Walker; Clara Grazian; Timothy J Davies; Timothy E A Peto; Derrick W Crook
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191
  3 in total
  16 in total

1.  On the Consequences of Poorly Defined Breakpoints for Rifampin Susceptibility Testing of Mycobacterium tuberculosis Complex.

Authors:  Claudio U Köser; Sophia B Georghiou; Thomas Schön; Max Salfinger
Journal:  J Clin Microbiol       Date:  2021-03-19       Impact factor: 5.948

2.  Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.

Authors:  Suha Kadura; Nicholas King; Maria Nakhoul; Hongya Zhu; Grant Theron; Claudio U Köser; Maha Farhat
Journal:  J Antimicrob Chemother       Date:  2020-08-01       Impact factor: 5.790

3.  Ethionamide Population Pharmacokinetic Model and Target Attainment in Multidrug-Resistant Tuberculosis.

Authors:  Mohammad H Al-Shaer; Anne-Grete Märtson; Wael A Alghamdi; Abdullah Alsultan; Guohua An; Shahriar Ahmed; Yosra Alkabab; Sayera Banu; Eric R Houpt; David Ashkin; David E Griffith; J Peter Cegielski; Scott K Heysell; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

4.  Role of Epistasis in Amikacin, Kanamycin, Bedaquiline, and Clofazimine Resistance in Mycobacterium tuberculosis Complex.

Authors:  Roger Vargas; Luca Freschi; Andrea Spitaleri; Sabira Tahseen; Ivan Barilar; Stefan Niemann; Paolo Miotto; Daniela Maria Cirillo; Claudio U Köser; Maha R Farhat
Journal:  Antimicrob Agents Chemother       Date:  2021-08-30       Impact factor: 5.938

Review 5.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis.

Authors:  Andrew Burke; Daniel Smith; Chris Coulter; Scott C Bell; Rachel Thomson; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2021-05-13       Impact factor: 5.577

6.  How To Optimally Combine Genotypic and Phenotypic Drug Susceptibility Testing Methods for Pyrazinamide.

Authors:  Claudio U Köser; Daniela M Cirillo; Paolo Miotto
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

7.  Isoniazid Resistance in Mycobacterium tuberculosis Is a Heterogeneous Phenotype Composed of Overlapping MIC Distributions with Different Underlying Resistance Mechanisms.

Authors:  Claudio U Köser; Daniela Maria Cirillo; Arash Ghodousi; Elisa Tagliani; Eranga Karunaratne; Stefan Niemann; Jennifer Perera
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

8.  Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis.

Authors:  Jan-Willem C Alffenaar; Tawanda Gumbo; Kelly E Dooley; Charles A Peloquin; Helen Mcilleron; Andre Zagorski; Daniela M Cirillo; Scott K Heysell; Denise Rossato Silva; Giovanni Battista Migliori
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

Review 9.  Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs.

Authors:  Marieke G G Sturkenboom; Anne-Grete Märtson; Elin M Svensson; Derek J Sloan; Kelly E Dooley; Simone H J van den Elsen; Paolo Denti; Charles A Peloquin; Rob E Aarnoutse; Jan-Willem C Alffenaar
Journal:  Clin Pharmacokinet       Date:  2021-03-06       Impact factor: 6.447

10.  Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex.

Authors:  Matthias Merker; Thomas A Kohl; Ivan Barilar; Sönke Andres; Philip W Fowler; Erja Chryssanthou; Kristian Ängeby; Pontus Jureen; Danesh Moradigaravand; Julian Parkhill; Sharon J Peacock; Thomas Schön; Florian P Maurer; Timothy Walker; Claudio Köser; Stefan Niemann
Journal:  Genome Med       Date:  2020-03-06       Impact factor: 11.117
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.